Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Bit Digital Inc (BTBT) Price & Performance

Amphastar Pharmaceuticals IncTrade
Bit Digital IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Bit Digital Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Bit Digital Inc trades at $1.35 (market cap $453.60M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.

AMPHBTBT
Market Cap
$863.95M$453.60M
Sector
HealthTechnology
52-Week High
$30.81$4.22
52-Week Low
$16.87$1.23
Enterprise Value
$1.26B$742.91M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Bit Digital Inc

BTBT trades at $1.38 with a 1.1% daily gain, showing modest momentum despite a bearish technical signal from moving averages. The company reported revenue of $113.56M in 2025 but posted a significant net loss of $80.32M, with profitability metrics like ROE at -38.98% indicating financial strain. Analyst coverage remains limited but unanimously positive, with 2 buy ratings and no hold or sell recommendations. Recent news highlights upcoming Q2 2026 earnings and mixed price target discussions.

The outlook for BTBT is clouded by persistent losses and negative cash flow from operations, though financing activities provide liquidity. Investment opportunities hinge on a potential earnings turnaround, while risks include sustained unprofitability, competitive pressures, and reliance on external funding. The stock's low valuation multiples may attract value seekers, but caution is warranted given the fundamental challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Bit Digital Inc

Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.

Read more on BTBT